ACA
CADL icon

Acorn Capital Advisors’s Candel Therapeutics CADL Stock Holding History

Acorn Capital Advisors’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36M Hold
3,497,948
– – 9.83% 4
2026
Q1 		$17.2M Buy
3,497,948
+917,431
+36% +$4.99M 4.89% 6
2025
Q4 		$14.6M Hold
2,580,517
– – 4.94% 6
2025
Q3 		$13.2M Hold
2,580,517
– – 6.68% 6
2025
Q2 		$13.1M Buy
2,580,517
+428,265
+20% +$2.2M 8.54% 5
2025
Q1 		$12.2M Buy
2,152,252
+212,608
+11% +$1.74M 8.11% 5
2024
Q4 		$16.8M Buy
+1,939,644
New +$11.5M 9.06% 3

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return

Acorn Capital Advisors's CADL Position: Q2 2026 in Review

Acorn Capital Advisors held its Candel Therapeutics (CADL) position steady in Q2 2026 at 3,497,948 shares worth $36M. The position accounts for 9.83% of the portfolio, ranked #4.

Acorn Capital Advisors first reported a position in CADL in Q4 2024 and has held it in 7 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • Acorn Capital Advisors held 3,497,948 shares of Candel Therapeutics worth $36M as of Q2 2026.
  • Acorn Capital Advisors left its Candel Therapeutics share count unchanged in Q2 2026.
  • Candel Therapeutics made up 9.83% of Acorn Capital Advisors's portfolio in Q2 2026, its #4 holding.
  • Acorn Capital Advisors first reported a position in Candel Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on Acorn Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.